赛登法律宣布，美国股东成立了一个小组，以通过对总部位于中国的海峰生物医药技术公司（股票代码：HFGB）的潜在接管程序，追回投资者资金。
Huifeng Bio-Pharmaceutical Technology, Inc. (Ticker: HFGB), is a British Virgin Islands corporation involved in the business of manufacturing and marketing pharmaceutical raw materials and ingredients, such as pharmaceuticals used for human and animals, nutraceuticals, cosmetics, functional drink and food. HFGB was de-listed from the NASDAQ in January 2013 after it stopped reporting to the Securities & Exchange Commission (“SEC”).
一些股东已与纽约的罗伯特·W·赛登恩律师联系，以代表一群股东，维护美国股东的权益，以制止那些损害投资者利益的行为，包括未能向美国证券交易委员会（SEC）报告，从而无法获得投资者可能获得的资本回报。 .
